Product Description: PA-8 is a potent, selective and orally active PACAP type I (PAC1) receptor antagonist. PA-8 inhibits the phosphorylation of CREB induced by PACAP in PAC1-, but not VPAC1- or VPAC2-receptor. PA-8 also inhibits PACAP-induced cAMP elevation with an IC50 of 2 nM[1][2].
Applications: COVID-19-immunoregulation
Formula: C17H18N4O4
References: [1]Ichiro Takasaki, et al. In Silico Screening Identified Novel Small-molecule Antagonists of PAC1 Receptor. J Pharmacol Exp Ther. 2018 Apr;365(1):1-8./[2]Ichiro Takasaki, et al. The novel small-molecule antagonist of PAC1 receptor attenuates formalin-induced inflammatory pain behaviors in mice. J Pharmacol Sci. 2019 Feb;139(2):129-132.
CAS Number: 878437-15-1
Molecular Weight: 342.35
Compound Purity: 97.02
Research Area: Inflammation/Immunology; Neurological Disease
Solubility: DMSO : 25 mg/mL (ultrasonic;warming;heat to 60°C)
Target: PACAP Receptor
Deutsch
English
